Nevertheless, according to the international guidelines for breast cancer treatment, the heterogeneity of the expression of diagnostic markers (e.g., HER2 or Ki67) should be taken into consideration when therapeutic decisions are made [50,51]. This evidence concerns the gene ERBB2 and breast carcinoma.